Comparison of Lifeloc vs. Cannabix and current state of development of the marijuana/cannabis breathalyzer:
Cannabix BLO/BLOZF:
Thus far testing has demonstrated the ability to isolate ?9-tetrahydrocannabinol (“THC”) and suppress background substrates and scientists are continuously working to improve resolving power.
The Company also reports that it has short listed 2 potential medical device development companies in order to develop the next version of the device as well as create multiple devices, that would be used for pilot testing.
This demonstrates the capability of the FAIMS device to isolate and detect THC from complex background matrix.
Recent testing with Beta 3.0 has shown the identification and first order separation of two key metabolites of ?9-tetrahydrocannabinol (“THC”), being 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol in standards. In addition, scientists have made significant progress towards using lower flow rates that will become important for user groups with poor lung function. Furthermore, engineers have been testing a new breath capture method that can hold THC breath samples in a stable manner for several days.
Lifeloc LCTC:
The marijuana breathalyzer took a step closer to realization with the detection of delta-9-THC (the psychoactive agent) captured from a vapor sample. The ability of our technology to detect delta-9-THC down to a concentration of 5 nanograms per milliliter has been demonstrated in our laboratories. Detection is accomplished through the SpinDx technology, licensed exclusively by Lifeloc Technologies for drugs of abuse from Sandia National Laboratory. More work is needed to convert this technology into a simple-to-operate device suitable for roadside testing. The next step is human testing of the collection and detection mechanism.
